-
Rituximab
- indication:For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
- pharmacologypharmacology:
- mechanism: The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
- toxicity:
- absorprion:
- halflife: 0.8 hours (mammalian reticulocytes, in vitro)
- roouteelimination:
- volumedistribution: * 3.1 L
- clearance: * 0.34 L/day [RA patients]